...
首页> 外文期刊>Journal of Neuroscience Research >Modulation of sensory neuron-specific receptors in the development of morphine tolerance and its neurochemical mechanisms.
【24h】

Modulation of sensory neuron-specific receptors in the development of morphine tolerance and its neurochemical mechanisms.

机译:感觉神经元特异性受体在吗啡耐受及其神经化学机制发展中的调控。

获取原文
获取原文并翻译 | 示例

摘要

Prevention of opiate tolerance is a critical issue in pain management. The present study was designed to characterize the pharmacological properties of sensory neuron-specific receptors (SNSR; also known as Mas-related gene receptors, or Mrg) for their modulation in the development of morphine tolerance and to investigate the underlying mechanism(s). Daily coadministration of the SNSR agonist BAM8-22 at a dose of 0.01 or 0.001, but not 1.0, nmol with morphine (intrathecally, or i.t., 20 microg/day) for 6 days significantly decreased the development of morphine tolerance. Coadministration of BAM8-22 (i.t., 1.0 nmol) on days 1, 3, and 5 completely blocked tolerance to morphine-induced analgesia. Intermittent coadministration of the structurally dissimilar SNSR agonist (Tyr(6))-2-MSH-6-12 (MSH; 5 nmol) also produced similar modulation. Chronic administration of morphine (20 microg, i.t.) increased expression of neuronal nitric oxide synthase (nNOS) and calcitonin gene-related peptide (CGRP) in superficial layers of the spinal cord and dorsal root ganglia. All these increases were abolished when BAM8-22 or MSH was intermittently coadministered. Furthermore, intermittent administration of BAM8-22 inhibited morphine-induced increase in protein kinase C gamma (PKC gamma) in both membrane and cytosol of spinal dorsal horn neurons. These results suggest that moderate activation of SNSR modulated morphine tolerance by inhibition of the PKC signaling pathway, leading to abolishment of enhancement of nNOS and CGRP. As SNSR are uniquely located ina subset of small-sized neurons in dorsal root and trigeminal ganglia, intermittent combination of SNSR agonist could be a promising adjunct for sustained use of opiates without central nervous system side effects.
机译:预防鸦片耐受是疼痛管理中的关键问题。本研究旨在描述感觉神经元特异性受体(SNSR;也称为Mas相关基因受体或Mrg)在吗啡耐受性发展中的调控作用,并研究其潜在机制。 SNSR激动剂BAM8-22每天以0.01或0.001(但不是1.0)nmol与吗啡的剂量(鞘内或即20微克/天)共同给药6天,可显着降低吗啡耐受性的发展。 BAM8-22(即1.0 nmol)在第1、3和5天的共同给药完全阻断了对吗啡诱导的镇痛的耐受性。结构上不同的SNSR激动剂(Tyr(6))-2-MSH-6-12(MSH; 5 nmol)的间歇共同给药也产生了类似的调节作用。长期服用吗啡(20微克,i.t。)会增加脊髓和背根神经节表层神经元型一氧化氮合酶(nNOS)和降钙素基因相关肽(CGRP)的表达。当间歇性地同时使用BAM8-22或MSH时,所有这些增加都被取消。此外,BAM8-22的间歇给药抑制了吗啡诱导的脊髓背角神经元膜和胞质溶胶中蛋白激酶Cγ(PKCγ)的增加。这些结果表明,通过抑制PKC信号通路,SNSR的适度激活调节了吗啡耐受性,从而取消了nNOS和CGRP增强作用。由于SNSR独特地位于背根和三叉神经节的小神经元的子集中,所以SNSR激动剂的间歇性组合可能是持续使用鸦片制剂而没有中枢神经系统副作用的有希望的辅助手段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号